Article Type : Short commentary
Authors : Wood M, Ebe K and Bando H
Keywords : Slowly progressive type 1 insulin-dependent diabetes mellitus (SPIDDM); Low-Carbohydrate Diet (LCD); Glutamic acid decarboxylase (GAD); Ketone bodies (KB); 3-hydroxybutyric acid (3-HB)
The patient was a 46-year-old man who presented with hyperglycemia and positive urine glucose 7 years ago. Since then, he has continued a super-low carbohydrate diet (LCD) and kept stable glucose variability. In 2019, his diabetic situation worsened and he received further evaluation. He showed positive glutamic acid decarboxylase (GAD) antibodies and was diagnosed with slowly progressive type 1 insulin-dependent diabetes mellitus (SPIDDM). The standard guideline of SPIDDM was presented by the Japan Diabetes Society (JDS) in 2023. Elevated levels of ketone bodies (KB) were found such as total-KB 624 ?M/L (26-122) and 3-hydroxybutyric acid (3-HB) 557 ?M/L (0-76).
In the area of diabetic practice,
slowly progressive type 1 insulin-dependent diabetes mellitus (SPIDDM) has been
one of the topics. It was first reported in 1993 [1], and several reports were
observed after that [2]. SPIDDM is situated between type 1 and type 2 diabetes
associated with various confusion. Few diagnostic criteria for SPIDDM have been
observed until 2012 [3]. Related to SPIDDM, other medical terms were present
including Latent autoimmune diabetes in adults (LADA) [4] and latent autoimmune
diabetes in youth (LADY) [5]. For the latest trend, the Japan Diabetes Society
(JDS) has established its criteria which can be used adequately for usual
clinical practice. The presentation of the report of the committee of JDS was
found for the diagnostic criteria of SPIDDM in 2023 [6]. For SPIDDM, several
types of islet-related autoantibodies are known, such as glutamic acid
decarboxylase antibody (GAD-Ab), Islet cell antibody (ICA),
Insulinoma-associated antigen-2(IA-2), zinc transporter 8?ZnT8?and
insulin autoantibody (IAA) [7,8]. 2023
SPIDDM diagnostic guidelines include the following: 1) Islet-related
autoantibodies are positive at some point or period during the course of the
disease, such as GAD-Ab, ICA, IA-2, ZnT8, and IAA, and 2) generally speaking,
when diabetes is diagnosed, ketosis or ketoacidosis is not necessarily present and
insulin therapy is not immediately required in order to correct hyperglycemia
[6].
Our diabetes group has continued
clinical research and practice for many patients with type 1, type 2 and SPIDDM
at length. Furthermore, we have developed a low carbohydrate diet (LCD)
medically and socially through the activity of the Japan LCD Promotion
Association (JLCDPA) [9]. Among them, we reported a case with positive GAD-Ab,
the effect of LCD, the honeymoon period, the effect of oral hypoglycemic agents
(OHAs), pregnancy with hyperglycemia, multiple medical problems and so on
[10-13]. Our activities have contributed to the development of correct and
adequate information and practice of diabetology through books, papers,
workshops and internet sites [14].
Recently, we have experienced an impressive case with SPIDDM. The
outline of the case associated with some perspectives is described in this
article.
Case Presentation
The patient was a 46-year-old man in 2023, and his diagnosis was SPIDDM, dyslipidemia, and allergic rhinitis. When he was 20 years old he weighed 58 kg, but he gained weight up to 70 kg at 30 years old. When he was 39 years old, he was pointed out to have hyperglycemia and glucosuria in 2016. He visited Dr. Koji Ebe at Takao Hospital in Kyoto for further evaluation and treatment. He was advised to start and continue the super-low carbohydrate diet (LCD) for years. By super-LCD, he has maintained 61kg ever since.
Table 1: Changes in laboratory data.
|
2019 |
2020 |
2021 |
2022 |
2023 |
|
|||
Sept |
Feb |
Sept |
May |
Dec |
Jun |
Dec |
Jul |
Units |
|
Lipids |
|
|
|
|
|
|
|
|
|
HDL |
105 |
107 |
107 |
112 |
116 |
116 |
107 |
113 |
(mg/dL) |
LDL |
97 |
111 |
103 |
97 |
95 |
83 |
92 |
75 |
(mg/dL) |
TG |
53 |
58 |
62 |
31 |
59 |
33 |
33 |
28 |
(mg/dL) |
Liver |
|
|
|
|
|
|
|
|
|
AST |
15 |
20 |
14 |
16 |
21 |
14 |
14 |
16 |
(U/L) |
ALT |
2 |
34 |
20 |
29 |
36 |
25 |
17 |
20 |
(U/L) |
GGT |
18 |
16 |
15 |
14 |
16 |
14 |
18 |
16 |
(U/L) |
Renal |
|
|
|
|
|
|
|
|
|
BUN |
18 |
21 |
12 |
15 |
17 |
16 |
17 |
16 |
(mg/dL) |
Cre |
0.95 |
0.84 |
0.89 |
0.97 |
0.90 |
0.92 |
0.74 |
0.90 |
(mg/dL) |
UA |
2.5 |
2.7 |
3.2 |
2.7 |
2.8 |
2.3 |
2.1 |
2.1 |
(mg/dL) |
Diabetes |
|
|
|
|
|
|
|
|
|
HbA1c |
6.2 |
6.1 |
5.9 |
5.7 |
5.8 |
5.9 |
5.9 |
6.0 |
(%) |
glucose |
90 |
96 |
92 |
106 |
90 |
108 |
102 |
111 |
(mg/dL) |
IRI |
|
3.1 |
|
2.6 |
|
|
|
|
(?U/mL) |
Ketone B. |
|
|
|
|
|
|
|
|
|
T-KB |
157 |
|
|
624 |
|
581 |
|
(26-122) |
(?M/L) |
AcAc |
36 |
|
|
67 |
|
46 |
|
(13-69) |
(?M/L) |
3-HB |
121 |
|
|
557 |
|
535 |
|
(0-76) |
(?M/L) |
T-KB: Total Ketone Bodies, AcAc: acetoacetate, 3-HB:
3-hydroxybutyrate, normal ranges for green color. |
During 2019, HbA1c was 6.2% in April
and rose to 6.8% in June. Then, he was hospitalized in July for thorough
evaluation and treatment. His physique was 172 cm, 61 kg, and BMI 20.6 m2/kg.
The exam results showed positive glutamic acid decarboxylase (GAD) antibody
(18.4?U/mL,
0-0.5 as normal range), C-peptide immunoreactivity (CPR) 1.29 ng/mL
(0.74-3.48), blood glucose 110 mg/dL, C-peptide index (CPI) = 1.17 (>1.2 for
normal). The CPI value was borderline low. In September 2019, he was diagnosed
with SPIDDM, and continued super-LCD. He has been an office worker and eaten a
set meal at his company's cafeteria for lunch, but he does not eat rice. Until
then, he had taken voglibose. However, he discontinued it because it was
unnecessary while he was on super-LCD. He also took protein bars (5g
carbohydrates, 20g protein) as supplements. Ketone bodies (KB) showed elevated
values of total-KB and 3-hydroxybutyric acid (3-HB) [15] (Table 1).
For 2020-2021, HbA1c maintained
5.9-6.2% associated with super-LCD meal. For the KB study, 3-HB was remarkably
elevated at 557 ?M/L (0-76). It indicated successful LCD continuation.
Abdominal echogram showed fatty liver. Laboratory results revealed that zinc
concentration was 92 ?g/dL (80-130), cystatin C 0.65 mg/L (0.58-0.87), and
urinary albumin 1.5 mg/gr?cre (<30), which were within the normal range.
During 2022-2023, 3-HB level showed
remarkably elevated as 557.0 ?M/L (0-76), associated with IRI 3.1 ?U/mL, body
weight 60kg, BMI 20.76 kg/m2, stable A1c of 5.8-5.9%. Other results
showed that NT-proBNP 30 (-126) pg/mL, TSH 3.93 ?IU/mL,
free T3 2.8 pg/mL, free T4 1.1 ng/dL, Cystatin 0.71 mg
/L, urine Albumin 2.8 mg/gr?cre (< 30), IRI 2.2 ?U/mL in September 2023. The
patient has continued muscle training to strengthen his abdominal muscles and
quadriceps nowadays.
Ethical Considerations
This patient complied with ordinary
ethical guidelines for the Helsinki Declaration. Further, certain comment was
observed for personal information. The related principle is found in ethical
rules for medical practice and research. This guideline has been regulated by
the Japanese government. It is included in both the Ministry of Health, Labor
and Welfare and the Ministry of Education, Culture, Sports, Science Technology.
The authors and collaborators have established our ethical committee about the
case. It exists in Takao Hospital, Kyoto, Japan. The committee has several
hospital staffs, including the president, physician in charge, registered
nutritionist, registered nurse, pharmacist, laboratory staff and legal professional.
These committee staffs discussed the case enough in a satisfactory manner. The
informed consent was taken from the case by the written data.
Discussion
The standard guidelines for SPIDDM
were announced in 2023 [6]. The first criterion is required for a diagnosis of
SPIDDM, which is met when islet-related autoantibodies (GAD-Ab, etc.) are
detectable. The second criterion is met when ketosis and ketoacidosis are
absent on initial diagnosis and insulin is not necessary for glycemic
correction. The third criterion is met
when at least three months have passed since the diagnosis of diabetes and
endogenous insulin production decreases enough that exogenous insulin is
required. Fasting serum C peptide would be less than 0.6 ng/ml. Probable SPIDDM
is defined as meeting only the first two criteria, while definite SPIDDM is
defined as meeting all three of the criteria mentioned above.
In this case, GAD antibody was
positive and SPIDDM was suspected. As a result of continuing super-LCD meal for
several years, general status has been stable in the light of glucose
variability. In other words, the length of the honeymoon period seems to have
been extended. During his clinical progress, the levels of total KB and 3-HB
were elevated, evidence of increased fatty acid utilization and LCD diet
adherence. KB and 3-HB presence has been long associated with LCD adherence.
SPIDDM is characterized by autoantibodies such as GAD-Ab. A case has been
reported in which the GAD-Ab value increased from 6.9 U/mL to 1600 U/mL during
the course of the disease, and the amount of insulin required decreased when
entering the honeymoon period [16]. For 3 years, GAD-Ab remained positive (40
U/mL) and HbA1c levels remained below 7%.
As to former management for SPIDDM
cases, insulin treatment was introduced at an early stage as a therapeutic
intervention. It was recommended because the data was compared with both
therapies of insulin and SU agents at that time [17]. In recent years, the
following recognition has been found. Even if GAD-Ab is positive, not all
diabetes that is insulin-independent SPIDDM by previous criteria will progress
to insulin-dependent status [18]. Furthermore, impressive reports of a few
cases with SPIDDM are found. DPP-4 inhibitors have been shown to slow the progression
to insulin dependence as a therapeutic intervention for SPIDDM by conventional
standards [19]. These phenomena have been suggested by the SPAN-S study [20].
Recent studies clarified pathologic
findings in the pancreas of patients with SPIDDM [3]. They include markers of
type 1 diabetes such as T-cell-mediated insulitis and pseudoatrophic islets, a
lack of amylin deposition to the islet cells and a pathologic marker of type 2
diabetes. From the consensus statement of an international expert panel, autoimmune
diabetes such as LADA seems to account for 2-12% of adult-onset diabetes cases
[21]). They have endotype heterogeneity with a personalized approach. The
American Diabetes Association (ADA) and the European Association for the Study
of Diabetes (EASD) consensus 2020 have proposed deviations for LADA from these
guidelines. They showed the recommended measurements of random C-peptide levels
and large clinical trials. If insulin secretion is maintained, treatment with
oral antidiabetic drugs other than SU drugs would be an option.
In summary, an impressive case of
SPIDDM with a longer honeymoon period was shown in this article with certain
perspectives. JDS presented a standard guideline for SPIDDM in 2023 that helps
the diagnosis and treatment [6]. Further, ADA/EASD consensus showed the
guidelines for recommending measurement of C-peptide and large clinical trials
[21]. We expect that this article will serve as a meaningful reference for
diabetic practice and research in the future.
Conflict of Interest
The authors declare no conflict of interest.
Funding
There was no funding received for this paper.
1.
Kobayashi T,
Tamemoto K, Nakanishi K, Kato N, Okubo M, Kajio H, et al. Immunogenetic and
clinical characterization of slowly progressive IDDM. Diabetes Care 1993; 16:
780-788.
8.
Kawasaki E. Anti-Islet
Autoantibodies in Type 1 Diabetes. Int J Mol Sci. 2023; 24: 10012.